Investigational drug · Phase 2
INV-6452
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "INV-6452"
First trial start
2025
Jul 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INV-6452", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer (Locally Advanced or Metastatic)
- Advanced Solid Cancers
- Metastatic (Stage IV) Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INV-6452" as an intervention, largest first.
Shenzhen Ionova Life Sciences Co., Ltd.Industry
NCT07612891 · 201 participants (planned) · Start Jul 4, 2025 · Primary completion Feb 4, 2028
Drug: INV-6452 · For: Breast Cancer (Locally Advanced or Metastatic); Advanced Solid Cancers; Metastatic (Stage IV) Breast Cancer and 2 more
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Breast Cancer (Locally Advanced or Metastatic)
- Dual-target CAR-NK cellsEB-DT-CAR-NK, Essen Biotech Dual-Target CAR-NKPhase 25 trials
Beijing Biotech · HER2-positive Breast Cancer, Non-Small Cell Lung Cancer, Breast Cancer (Locally Advanced or Metastatic)
- BL0175Phase 21 trial
Shanghai Best-Link Bioscience, LLC · Breast Cancer (Locally Advanced or Metastatic)
- GB268Phase 21 trial
Eddingpharm (Zhuhai) Co., Ltd. · Breast Cancer (Locally Advanced or Metastatic)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.